Akari Therapeutics Plc (AKTX)

Name: Akari Therapeutics Plc Financial Statements
Creator: Quarter Results

Healthcare | Biotechnology

Latest reporting period: 2026-03-31

Latest Quarter

2026-03-31

Revenue

$0.0

Net Income

-$14.5M

Operating Margin

N/A

Free Cash Flow

-$10.6M

Debt / Assets

56.0%

Values are in USD and rounded to the nearest whole number unless noted.

Swipe horizontally to view all columns.

Income statement quarterly history for Akari Therapeutics Plc (AKTX).
Income Statement (Quarterly)	2026-03-31	2025-03-31	2024-12-31	2024-09-30
Revenue	0	0	0	0
Cost of Revenue	0	0	0	0
Gross Profit	0	0	0	0
Operating Expenses
R&D Expenses	0	0	0	0
SG&A Expenses	2,169,000	2,712,000	3,048,000	1,709,000
Operating Expenses	15,758,000	3,525,000	5,278,000	2,927,000
Operating Income	-15,758,000	-3,525,000	-5,278,000	-2,927,000
Interest Expense	61,000	55,000	124,000	69,000
Income Before Tax	-15,314,000	-3,705,000	-3,772,000	-2,895,000
Income Tax Expense	-859,000	0	0	0
Net Income	-14,455,000	-3,705,000	-3,772,000	-2,895,000
Per Share
EPS	-976.00	-20.00	-40.00	-20.00
EPS Diluted	0.00	0.00	0.00	0.00

Income statement annual history for Akari Therapeutics Plc (AKTX).
Income Statement (Annual)	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Revenue	0	0	0	0	0
Cost of Revenue	0	0	4,000	3,708	0
Gross Profit	0	0	-4,000	-3,708	0
Operating Expenses
R&D Expenses	0	0	0	0	0
SG&A Expenses	9,280,000	9,664,000	11,356,000	13,527,311	8,080,681
Operating Expenses	17,275,000	21,643,000	16,806,000	23,891,000	17,214,136
Operating Income	-17,275,000	-21,643,000	-16,806,000	-23,088,208	-17,214,136
Interest Expense	949,000	-244,000	0	-5,340,146	0
Income Before Tax	-18,301,000	-19,791,000	-10,008,000	-17,748,062	-17,424,237
Income Tax Expense	-1,003,000	0	0	-10,775,810	0
Net Income	-17,298,000	-19,791,000	-10,008,000	-6,972,252	-17,424,237
Per Share
EPS	-20,800.00	-1,660.00	-200.00	-2.23	-0.41
EPS Diluted	0.00	0.00	0.00	0.00	0.00

Balance sheet quarterly history for Akari Therapeutics Plc (AKTX).
Balance Sheet (Quarterly)	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Assets
Cash and Cash Equivalents	2,599,000	3,845,000	13,249,945	9,361,270
Short Term Investments	0	0	0	0
Net Receivables	201,000	0	2,951,000	0
Inventory	0	0	-2,485,756	0
Total Current Assets	2,952,000	4,341,000	13,814,732	11,625,099
Property Plant Equipment	0	0	0	0
Goodwill and Intangibles	47,610,000	14,000	16,880	22,929
Total Assets	50,562,000	4,355,000	13,831,612	11,648,028
Liabilities
Account Payables	12,407,000	1,671,000	946,658	1,788,563
Short Term Debt	3,260,000	0	0	0
Total Current Liabilities	19,910,000	4,584,000	12,040,866	6,093,446
Long Term Debt	0	0	0	0
Total Liabilities	28,333,000	4,584,000	12,040,866	6,093,446
Shareholders Equity
Retained Earnings	-247,252,000	-227,461,000	-217,453,110	-199,705,048
Total Shareholders Equity	22,229,000	-229,000	1,790,746	5,554,582

Balance sheet annual history for Akari Therapeutics Plc (AKTX).
Balance Sheet (Annual)	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31
Assets
Cash and Cash Equivalents	2,599,000	3,845,000	13,249,945	9,361,270	14,055,777
Short Term Investments	0	0	0	0	0
Net Receivables	201,000	0	2,951,000	0	0
Inventory	0	0	-2,485,756	0	0
Total Current Assets	2,952,000	4,341,000	13,814,732	11,625,099	14,577,657
Property Plant Equipment	0	0	0	0	0
Goodwill and Intangibles	47,610,000	14,000	16,880	22,929	27,150
Total Assets	50,562,000	4,355,000	13,831,612	11,648,028	14,604,807
Liabilities
Account Payables	12,407,000	1,671,000	946,658	1,788,563	3,380,782
Short Term Debt	3,260,000	0	0	0	0
Total Current Liabilities	19,910,000	4,584,000	12,040,866	6,093,446	5,220,488
Long Term Debt	0	0	0	0	0
Total Liabilities	28,333,000	4,584,000	12,040,866	6,093,446	5,220,488
Shareholders Equity
Retained Earnings	-247,252,000	-227,461,000	-217,453,110	-199,705,048	-182,280,811
Total Shareholders Equity	22,229,000	-229,000	1,790,746	5,554,582	9,384,319

Cash flow quarterly history for Akari Therapeutics Plc (AKTX).
Cash Flow Statement (Quarterly)	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Operating Activities
Net Income	-17,298,000	-19,791,000	-10,008,000	-17,748,062
Depreciation & Amortization	0	14,000	4,000	3,708
Stock Based Compensation	2,890,000	2,245,000	1,150,000	735,107
Change in Working Capital	-404,000	6,539,000	70,000	821,893
Operating Cash Flow	-10,568,000	-12,552,000	-16,432,000	-21,504,522
Investing Activities
Capital Expenditure	0	0	0	0
Investments	0	0	0	0
Investing Cash Flow	0	382,000	0	0
Financing Activities
Debt Repayment	1,047,000	-855,000	0	0
Common Stock Issued/Repurchased	12,124,000	11,815,000	7,020,000	25,193,991
Dividends Paid	0	0	0	0
Financing Cash Flow	13,171,000	10,988,000	7,020,000	25,288,109
Summary
Free Cash Flow	-10,568,000	-12,552,000	-16,432,000	-21,504,522
Net Change in Cash	2,604,000	-1,186,000	-9,405,000	3,888,675

Cash flow annual history for Akari Therapeutics Plc (AKTX).
Cash Flow Statement (Annual)	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Operating Activities
Net Income	-17,298,000	-19,791,000	-10,008,000	-17,748,062	-17,424,237
Depreciation & Amortization	0	14,000	4,000	3,708	4,126
Stock Based Compensation	2,890,000	2,245,000	1,150,000	735,107	314,650
Change in Working Capital	-404,000	6,539,000	70,000	821,893	-1,983,570
Operating Cash Flow	-10,568,000	-12,552,000	-16,432,000	-21,504,522	-18,846,528
Investing Activities
Capital Expenditure	0	0	0	0	0
Investments	0	0	0	0	0
Investing Cash Flow	0	382,000	0	0	0
Financing Activities
Debt Repayment	1,047,000	-855,000	0	0	0
Common Stock Issued/Repurchased	12,124,000	11,815,000	7,020,000	25,193,991	14,292,753
Dividends Paid	0	0	0	0	0
Financing Cash Flow	13,171,000	10,988,000	7,020,000	25,288,109	14,292,753
Summary
Free Cash Flow	-10,568,000	-12,552,000	-16,432,000	-21,504,522	-18,846,528
Net Change in Cash	2,604,000	-1,186,000	-9,405,000	3,888,675	-4,694,507